Erlotinib is a receptor tyrosine kinase inhibitor of EGFR, which is approved clinically in certain instances of metastatic non-small cell lung cancer or pancreatic cancer, and its role in suppressing tumor angiogenesis has also been described40. The gene discussed is NTRK1; the disease is non-small cell lung carcinoma.